Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: Sir Auric Goldfinger who wrote (11724)	6/6/2003 4:19:03 PM
From: RockyBalboa	Respond to of 19428

Would you call them "fish"? Nice definition... Press Release Source: Boots & Coots International Well Control, Inc. Boots & Coots Addresses Frequently Asked Shareholder Questions ... Jerry Winchester, CEO for Boots & Coots, stated, "The recent resurgence of interest in the Company has brought a new wave of investors that may not be fully aware of recent developments. ...

To: Sir Auric Goldfinger who wrote (11724)	6/6/2003 9:14:08 PM
From: Hank	Read Replies (2) \| Respond to of 19428

OXGN- This one smells fishy to me. I don't care about the FDA "fast track" crap. That doesn't change the facts given their lead drug is already in phase 2 and "fast track" doesn't guarantee approval. Look at this thing jump. I get a queasy feeling every time I look at the chart. Only 10 employees and they claim to have beaten everybody else to the punch in angiogenesis. Give me a break. The type of thyroid cancer the lead drug is seeking approval for is rare at best. Any dirt under the carpet?